HEALTHCARE News & Analysis

Trump’s announcement could directly affect CSL, but we expect the firm to respond accordingly.

This healthcare company still has plenty of growth potential, but it’s been a rocky road for investors recently.

Sigma’s merger with Chemist Warehouse has brought one of Australia’s best retail businesses to the public.

The sell-off in this moated healthcare company ignores strong potential for revenue growth and margin improvement.

We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.

Niche play with more growth potential than many investors give it credit for.

We assume that pharmaceutical tariffs will be enacted. While this could bring short-term margin pressure, we have not changed our valuations.

The ASX's biggest healthcare name saw its shares fall after reporting first-half results.

Find out how you can benefit from global megatrends. 

Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.